July 2022: Notable Drug Approvals


Pharmacologic Class


More Information

Dermatological Disorders
Opzelura (ruxolitinib cream) Janus kinase inhibitor Treatment of nonsegmental vitiligo in patients 12 years of age and older. Opzelura Drug Monograph
Zoryve (roflumilast cream) Phosphodiesterase-4 inhibitor Treatment of plaque psoriasis in patients 12 years of age and older. Zoryve Cream Approved for Plaque Psoriasis
Neurologic Disorders
Zonisade (zonisamide oral suspension) Carbonic anhydrase inhibitor Adjunctive therapy for the treatment of partial-onset seizures in patients 16 years of age and older. Oral Suspension Formulation of Zonisamide Gets FDA Approval
Xalkori (crizotinib capsules) Tyrosine kinase inhibitor Treatment of patients 1 year and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase-positive myofibroblastic tumor. Xalkori Drug Monograph
Diagnostic Agents
Bludigo (indigotindisulfonate sodium injection) Diagnostic dye For use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. Bludigo Approved as Diagnostic Dye for Cystoscopic Assessment of Ureters